Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

Comment by Boomskidon Feb 27, 2023 7:55pm
80 Views
Post# 35308461

RE:Tomorrow is Rare Disease Day...

RE:Tomorrow is Rare Disease Day...@BioasisUS says, "As we approach #RareDiseaseDay, we're reminded of the need for innovative treatments for these often-neglected conditions. At Bioasis, we're proud to be working towards that goal by developing cutting-edge therapies for rare brain disorders. 

Bwah hahahaha!

Yes, Bioasis does need to be reminded of the need for blah blah blah...

What a smarmy response!

Bioasis has purposefully played down what could be one of the most valuable tools in the treatment of CNS rare diseases, xB3. The company's share price has dropped over 95% since Dr. Deborah Rathjen became CEO.

But you know, I'll bet that Rathjen believes that post she made on Twitter.

We know poof believes it.

1.5¢ !!

jd

<< Previous
Bullboard Posts
Next >>